journal
MENU ▼
Read by QxMD icon Read
search

Rheumatology and Therapy

journal
https://www.readbyqxmd.com/read/29149437/a-blinded-randomized-placebo-controlled-study-to-investigate-the-efficacy-and-safety-of-ferric-carboxymaltose-in-iron-deficient-patients-with-fibromyalgia
#1
Chad S Boomershine, Todd A Koch, David Morris
INTRODUCTION: This study sought to compare efficacy and safety of ferric carboxymaltose vs. placebo in iron-deficient patients with fibromyalgia. METHODS: This blinded, placebo-controlled, phase 2 study randomized adults with fibromyalgia and Revised Fibromyalgia Impact Questionnaire (FIQR) scores ≥ 60, ferritin levels < 0.05 µg/ml, and transferrin saturation < 20% (1:1) to receive ferric carboxymaltose [15 mg/kg (up to 750 mg)], or placebo (15 cc normal saline) intravenously on study days 0 and 5...
November 17, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29138986/secukinumab-in-active-rheumatoid-arthritis-after-anti-tnf%C3%AE-therapy-a-randomized-double-blind-placebo-controlled-phase-3-study
#2
Hasan Tahir, Atul Deodhar, Mark Genovese, Tsutomu Takeuchi, Jacob Aelion, Filip Van den Bosch, Sibylle Haemmerle, Hanno B Richards
INTRODUCTION: 'REASSURE' (NCT01377012), a phase 3 study, evaluated the efficacy and safety of secukinumab in patients with active rheumatoid arthritis (RA) who had an inadequate response to, or intolerance of, tumor necrosis factor inhibitors (TNF-inhibitors). METHODS: A total of 637 patients were randomized (1:1:1) to receive intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous secukinumab 150 mg or 75 mg every 4 weeks (starting from week 8) or placebo at the same dosing schedule...
November 14, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29071588/a-retrospective-medical-record-review-of-utilization-patterns-and-medical-resource-use-associated-with-repository-corticotropin-injection-among-patients-with-rheumatologic-diseases-in-the-united-states
#3
Winnie W Nelson, Michael J Philbin, Jack R Gallagher, Kylee Heap, Susan Carroll, George J Wan
INTRODUCTION: Repository corticotropin injection (RCI) has anti-inflammatory and immune-modulatory effects and is approved for multiple indications, including several rheumatologic conditions. The aims of this nationally representative, retrospective, observational study were to describe patient characteristics, RCI treatment patterns, and barriers to RCI use in patients with rheumatologic disease, and to compare medical resource use (MRU) before and after RCI therapy. METHODS: A random sample of US physicians was recruited to abstract the medical records of deidentified patients with a diagnosis of rheumatoid arthritis (RA), psoriatic arthritis (PsA), dermatomyositis/polymyositis (DM/PM), or systemic lupus erythematosus (SLE) who had been treated with RCI in the previous 24 months...
October 25, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29032452/treatment-outcomes-with-biosimilars-be-aware-of-the-nocebo-effect
#4
REVIEW
Mourad F Rezk, Burkhard Pieper
Over the years, biologic agents have proven their importance in the management of chronic autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Biosimilars, which are biologic medicines, are highly similar to approved biologic medicines, and are comprehensively developed and rigorously tested to ensure efficacy and safety are similar to the reference product. A broader armamentarium of biosimilars is expected to improve patients' access to safe and effective biologic medicines, thus offering benefits to healthcare systems around the globe...
October 14, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29022197/a-case-of-recalcitrant-psoriatic-arthritis-to-tnf-inhibitors-improved-after-administration-of-secukinumab-an-il-17a-inhibitor
#5
Eleftherios Pelechas, Tereza Memi, Paraskevi V Voulgari, Alexandros A Drosos
Psoriatic arthritis (PsA) is a unique inflammatory arthritis due to the fact that patients have to deal not only with pain but also with their skin appearance, which may have a detrimental effect on their everyday lives and psychology. Treating a patient with PsA, improving both the musculoskeletal and skin symptoms is a challenge for the clinical rheumatologist. In this case, we present a patient of recalcitrant PsA to tumor necrosis factor inhibitors (TNFi) who had an exceptional improvement after administration of the interleukin-17A inhibitor (IL-17Ai) secukinumab...
October 11, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28956324/treatment-with-allopurinol-is-associated-with-lower-risk-of-acute-kidney-injury-in-patients-with-gout-a-retrospective-analysis-of-a-nested-cohort
#6
Fernando Perez-Ruiz
INTRODUCTION: Gout is characterized by recurrent episodes of acute inflammation of joint structures, called gout flares, and flares are commonly treated with nonsteroidal anti-inflammatory drugs (NSAIDs). The objective of the study was to evaluate risk factors associated with acute kidney injury (AKI) attributed to NSAIDs in a cohort of patients who were exposed to NSAIDs to treat gout flares prior to urate-lowering therapy. METHODS: Retrospective analysis of a nested cohort of 983 gout patients in whom general variables (age, gender, renal function, ethanol intake, hypertension, hyperlipidemia, diabetes, vascular events, diuretic use) and also variables related to gout and severity of gout (serum urate levels, number for flares per year, presence of tophi, joint distribution, X-ray involvement, previous urate-lowering therapy) were available for analysis...
September 27, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28956301/cost-effectiveness-of-golimumab-in-ankylosing-spondylitis-from-the-uk-payer-perspective
#7
Rebekah H Borse, Chloe Brown, Noemi Muszbek, Mohammad Ashraf Chaudhary, Sumesh Kachroo
INTRODUCTION: Golimumab is a tumor necrosis factor-α (TNF-α) inhibitor for treatment of patients with severe, active ankylosing spondylitis. This study evaluated the cost-effectiveness of golimumab compared with conventional care and other TNF-α inhibitors in treatment of AS from the UK National Health Service perspective. METHODS: A long-term Markov model (with initial decision tree) was developed to simulate the progression of a hypothetical cohort of patients with active AS over a lifetime...
September 27, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28956300/chronic-disease-and-self-injection-ethnographic-investigations-into-the-patient-experience-during-treatment
#8
Michael Schiff, Shane Saunderson, Irina Mountian, Paul Hartley
INTRODUCTION: Drug administration by self-injection provides an option to treat chronic inflammatory diseases such as rheumatoid arthritis (RA) and Crohn's disease (CD). However, a negative self-injection experience for patients may reduce patient adherence to the recommended treatment regimen. In this study, a holistic approach was used to identify common themes along the treatment pathway and at self-injection that, if changed, could improve patient experience and treatment outcomes...
September 27, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28936808/impact-of-tocilizumab-monotherapy-on-clinical-and-patient-reported-quality-of-life-outcomes-in-patients-with-rheumatoid-arthritis
#9
Leslie R Harrold, Ani John, George W Reed, Tmirah Haselkorn, Chitra Karki, YouFu Li, Jennie Best, Steve Zlotnick, Joel M Kremer, Jeffrey D Greenberg
INTRODUCTION: Tocilizumab (TCZ) monotherapy has been proven as an effective treatment for rheumatoid arthritis (RA) in clinical trials. However, there are limited data available regarding the effectiveness of TCZ monotherapy in real-world clinical settings in the United States. The objective of this study was to evaluate the impact of TCZ monotherapy on disease activity and patient-reported outcomes (PROs) in a US-based observational cohort of patients with RA seen in routine clinical practice...
September 21, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28900875/single-arm-study-of-etanercept-in-adult-patients-with-moderate-to-severe-rheumatoid-arthritis-who-failed-adalimumab-treatment
#10
Louis Bessette, Majed Khraishi, Alan J Kivitz, Arunan Kaliyaperumal, Rama Grantab, Melanie Poulin-Costello, Maya Isaila, David Collier
INTRODUCTION: To evaluate the efficacy and safety of etanercept treatment in adult patients with moderate to severe rheumatoid arthritis (RA) who failed to respond (primary failure) or lost a satisfactory response (secondary failure) to adalimumab. METHODS: All patients discontinued prior adalimumab treatment and continued methotrexate with etanercept 50 mg once weekly for 24 weeks. The primary study endpoint was American College of Rheumatology 20% improvement criteria (ACR20) at week 12...
September 12, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28849401/a-review-of-the-use-of-secukinumab-for-psoriatic-arthritis
#11
REVIEW
Nupur U Patel, Nora C Vera, Emily Rose Shealy, Margaret Wetzel, Steven R Feldman
Psoriatic arthritis (PsA) is a chronic, seronegative spondyloarthropathy associated with psoriasis (PsO). Treatment options range from non-pharmacologic measures to NSAIDS, DMARDs, and biologics, depending on patient presentation. Secukinumab (Cosentyx©) is a new biologic treatment option that was approved for use in treating adult patients with PsA in October 2016. Our paper explores the clinical trial evidence available for secukinumab to examine its safety and efficacy as a therapeutic agent for the treatment of PsA...
August 28, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28840531/long-term-effectiveness-of-adalimumab-in-patients-with-rheumatoid-arthritis-an-observational-analysis-from-the-corrona-rheumatoid-arthritis-registry
#12
Dimitrios A Pappas, Joel M Kremer, Jenny Griffith, George Reed, Bob Salim, Chitra Karki, Vishvas Garg
INTRODUCTION: Current recommendations for the management of rheumatoid arthritis (RA) focus on a treat-to-target approach with the objective of maximizing long-term health-related quality-of-life in patients with RA. Published studies from randomized clinical trials have reported limited data regarding the long-term efficacy and safety of adalimumab in patients with RA. This study aims to evaluate the long-term (10+ years) persistency and effectiveness of adalimumab in patients with RA in a real-world setting...
August 24, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28831751/discontinuation-of-biologic-therapy-in-rheumatoid-arthritis-analysis-from-the-corrona-ra-registry
#13
Vibeke Strand, Paul Miller, Setareh A Williams, Katherine Saunders, Shannon Grant, Joel Kremer
INTRODUCTION: Despite the availability of multiple effective therapies, discontinuation/switching of treatment is common for many patients with rheumatoid arthritis (RA). This study was designed to examine initiation of biologic disease-modifying anti-rheumatic drugs (bDMARDs) within the Consortium of Rheumatology Researchers of North America (Corrona) RA Registry, and characterize reasons for discontinuation. METHODS: Inclusion criteria were: Corrona-registered adults (≥18 years) with RA (2002-2011); age of RA onset: ≥16 years; ≥6 months' follow-up after initiation of first/subsequent bDMARD...
August 22, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28831712/treatment-with-biologicals-in-rheumatoid-arthritis-an-overview
#14
REVIEW
Philipp Rein, Ruediger B Mueller
Management and therapy of rheumatoid arthritis (RA) has been revolutionized by the development and approval of the first biological disease-modifying antirheumatic drugs (bDMARDs) targeting tumor necrosis factor (TNF) α at the end of the last century. Today, numerous efficacious agents with different modes of action are available and achievement of clinical remission or, at least, low disease activity is the target of therapy. Early therapeutic interventions aiming at a defined goal of therapy (treat to target) are supposed to halt inflammation, improving symptoms and signs, and preserving structural integrity of the joints in RA...
August 22, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28819927/switching-from-immediate-release-to-delayed-release-prednisone-in-moderate-to-severe-rheumatoid-arthritis-a-practice-based-clinical-study
#15
Ara H Dikranian, Rubaiya Mallay, Mike Marshall, Megan Francis-Sedlak, Robert J Holt
INTRODUCTION: Rheumatoid arthritis (RA) produces debilitating morning stiffness. Exogenous glucocorticoids can help with these symptoms when timed appropriately. Bedtime dosing of delayed-release prednisone (DR-prednisone) matches the rise of inflammatory cytokines before awakening and can improve stiffness and other RA symptoms. A prospective open-label study was conducted in patients currently on stable doses of immediate-release prednisone (IR-prednisone) who were switched to DR-prednisone to analyze the incremental benefit of better timed and lower dose glucocorticoid therapy...
August 17, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28815445/identification-and-treatment-optimization-of-comorbid-depression-in-rheumatoid-arthritis
#16
Mellissa H Withers, Louella T Gonzalez, George A Karpouzas
Patients with rheumatoid arthritis (RA) suffer from high rates of depression but depression often remains undiagnosed and untreated among RA patients. Because of its high prevalence and its profound impact on functional disability and health-related quality of life, prompt recognition and management of comorbid depression is urgently needed in patients with RA. Rheumatologists face the challenge of addressing depression in their clinical interactions with patients. The purpose of this paper is to present the prevalence of comorbid depression in RA, to delineate the consequences of depression among RA patients, to discuss the barriers to the identification of depression among RA patients, and to outline a set of recommendations to identify and treat comorbid depression that could be implemented within the rheumatology clinic setting...
August 16, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28808949/practical-management-of-respiratory-comorbidities-in-patients-with-rheumatoid-arthritis
#17
REVIEW
James Bluett, Meghna Jani, Deborah P M Symmons
Lung disease is one of the most common causes of extra-articular morbidity and mortality in patients with rheumatoid arthritis (RA). Development of pulmonary manifestations may be due to the systemic disease itself; to serious respiratory adverse events such as pneumonitis and infections secondary to therapy; or to lifestyle habits such as smoking. Rheumatologists often need to make important treatment decisions and plan future care in RA patients with respiratory comorbidities, despite the absence of clear evidence or consensus...
August 14, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28791611/chronic-autoimmune-epithelitis-in-sj%C3%A3-gren-s-syndrome-and-primary-biliary-cholangitis-a-comprehensive-review
#18
REVIEW
Carlo Selmi, M Eric Gershwin
Within the spectrum of autoimmune diseases, Sjögren's syndrome and primary biliary cholangitis are exemplary and can be coined as chronic epithelitis based on their frequent coexistence in clinical practice and the highly specific immune-mediated injury of the small bile ducts and the exocrine glands. The pathogenic mechanisms underlying the diseases are similar, with apoptosis being the key element leading to organ-specific immune-mediated injury directed against the small bile ducts and salivary gland epithelia, respectively along with similar epidemiological features, such as female predominance and the age of onset in the fifth decade of life...
August 8, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28762213/comparative-effectiveness-of-adalimumab-versus-secukinumab-for-the-treatment-of-psoriatic-arthritis-a-matching-adjusted-indirect-comparison
#19
Vibeke Strand, Keith A Betts, Manish Mittal, Jinlin Song, Martha Skup, Avani Joshi
INTRODUCTION: The Phase III FUTURE I and II trials demonstrated the clinical efficacy of secukinumab in active psoriatic arthritis (PsA). In the absence of head-to-head trials, this study compared the clinical efficacy and cost effectiveness of adalimumab 40 mg versus secukinumab 150 and 300 mg for the treatment of active PsA. METHODS: A matching-adjusted indirect comparison was conducted using individual patient data from the ADEPT trial of adalimumab and published data from FUTURE I and II...
July 31, 2017: Rheumatology and Therapy
https://www.readbyqxmd.com/read/28755063/brazilian-experience-of-the-treatment-of-alopecia-universalis-with-the-novel-antirheumatic-therapy-tofacitinib-a-case-series
#20
Morton Scheinberg, Regina Adalva de Lucena Couto Océa, Boris Afonso Cruz, Sineida Berbert Ferreira
INTRODUCTION: Alopecia universalis is an autoimmune disorder for which there is no known effective therapy. Tofacitinib-a novel antirheumatic therapy for rheumatoid arthritis-has been shown in some reports to induce sustained hair growth in patients with alopecia universalis. CASE SERIES: Here, we review the experiences of four different rheumatologists across the country regarding four Brazilian patients with alopecia universalis who were treated with tofacitinib ...
July 28, 2017: Rheumatology and Therapy
journal
journal
53766
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"